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ABSTRACT
The objectives of this study were to quantify the ef-
fect of an intrauterine infusion of cephapirin on repro-
ductive performance at first service of postpartum dairy 
cows affected by purulent vaginal discharge (PVD) and 
cytological endometritis (ENDO) using different diag-
nostic strategies, and to determine if the presence of 
prolonged anovulation would influence the magnitude 
of treatment benefit. In total, 2,259 Holstein cows in 28 
herds were enrolled in a randomized clinical trial. At 
35 (±7) days in milk (DIM), cows were diagnosed with 
PVD using the Metricheck device (Simcro, Hamilton, 
New Zealand), with cytological endometritis using en-
dometrial cytology (ENDO-CYTO), and with cytologi-
cal endometritis using leukocyte esterase (ENDO-LE). 
Regardless of reproductive tract disease status, cows 
were randomly assigned to receive an intrauterine cep-
hapirin infusion or to not be treated. Serum progester-
one was measured at 35 and 49 (±7) DIM (14 d apart); 
cows were considered to have prolonged anovulation 
if progesterone was <1 ng/mL at both times. Repro-
ductive events of cows were collected until 200 DIM. 
Statistical analyses were conducted using multivariable 
mixed logistic regression models. Intrauterine cepha-
pirin treatment was associated with an increased first-
service pregnancy risk in cows diagnosed with PVD (no 
treatment: 15.4%; treatment: 31.4%), ENDO-CYTO 
(no treatment: 16.2%, treatment: 24.4%), and ENDO-
LE (no treatment: 15.8%; treatment: 25.1%), but not 
in cows unaffected by any form of reproductive tract 
disease (no treatment: 34.8%; treatment: 32.6%). Cep-
hapirin treatment was also associated with an increased 
first-service reproductive performance in cows affected 
simultaneously by both PVD and ENDO-CYTO (no 
treatment: 8.7%; treatment: 23.4%). The effect of 
cephapirin treatment in anovular cows (no treatment: 
21.0%; treatment: 26.4%) was numerically lower than 
in cyclic cows (no treatment: 22.7%; treatment: 34.1%). 
Overall, an intrauterine infusion of cephapirin improved 
first-service pregnancy risk in cows with postpartum re-
productive tract disease and this effect was influenced 
by postpartum anovulation status.
Key words: dairy cow, treatment, endometritis, 
cephapirin
INTRODUCTION
Purulent vaginal discharge (PVD) and cytological 
endometritis (ENDO) are associated with impaired 
subsequent reproductive performance in postpartum 
dairy cows (LeBlanc et al., 2002a; Gilbert et al., 2005; 
Dubuc et al., 2010). The use of an intrauterine infusion 
of cephapirin is approved in Canada (Merck Animal 
Health, Montréal, Canada) and other countries for the 
treatment of PVD. Intrauterine cephapirin infusion has 
been shown by multiple studies to improve reproductive 
performance of dairy cows with PVD (LeBlanc et al., 
2002b; Runciman et al., 2008), but little data are avail-
able for cows with ENDO (Kasimanickam et al., 2005). 
Interestingly, no studies have diagnosed and simultane-
ously reported PVD and ENDO when investigating the 
efficacy of an intrauterine cephapirin infusion. Using 
such an approach could provide more insight into the 
benefit of performing reproductive tract disease sur-
veillance in dairy herds and on the benefit of treating 
affected cows.
Reproductive tract disease diagnostic tools such as 
the Metricheck (Simcro, Hamilton, New Zealand; Mc-
Dougall et al., 2007; Dubuc et al., 2010), vaginoscope 
(LeBlanc et al., 2002a; Runciman et al., 2009), endo-
metrial cytobrush (Kasimanickam et al., 2004; Dubuc 
et al., 2010), and endometrial leukocyte esterase (LE; 
Cheong et al., 2012; Couto et al., 2013) tests have been 
shown to be useful for the identification of cows with 
poorer subsequent reproductive performance. However, 
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most of these studies evaluated only the association 
between one form of disease (PVD or ENDO) and 
subsequent reproductive performance. A recent study 
determined that the best pair of diagnostic criteria 
when using the Metricheck and cytobrush techniques 
simultaneously was ≥4 (purulent or worse vaginal 
discharge; PVD) and ≥6% polymorphonuclear cells 
(ENDO-CYTO), respectively (Denis-Robichaud and 
Dubuc, 2015). Similarly, in the same report, the optimal 
pair of diagnostic criteria when using the Metricheck 
and leukocyte esterase techniques was ≥4 (purulent or 
worse vaginal discharge; PVD) and ≥1 (small amounts 
of leukocytes; ENDO-LE), respectively. The diagnos-
tic performance of using these tests was reported, but 
it remains unclear at this time whether a treatment 
with intrauterine cephapirin infusion of cows diagnosed 
with PVD, ENDO-CYTO, or ENDO-LE using these 
strategies would improve their subsequent reproductive 
performance.
Although the use of intrauterine cephapirin therapy 
has been shown to be beneficial for cows with PVD 
(LeBlanc et al., 2002b; Runciman et al., 2008), only 
one study has investigated the effect of having or not 
a corpus luteum at the time of infusion (as a proxy for 
identification of anovular cows; LeBlanc et al., 2002b). 
It seems intuitive that the positive effect of cephapirin 
treatment on cows affected by PVD, ENDO-CYTO, 
or ENDO-LE may be modulated by ovulatory status. 
Prolonged postpartum anovulation has been associated 
with poorer reproductive performance (Walsh et al., 
2007; Galvão et al., 2010; Dubuc et al., 2012) and the 
positive effect of intrauterine cephapirin in these cows 
could be influenced by it. A recent study reported that 
prolonged anovulation and cytological endometritis 
have additive detrimental effects on subsequent repro-
ductive performance of cows (Vieira-Neto et al., 2014). 
Unfortunately, it remains unclear whether the presence 
of prolonged anovulation reduces the benefit of cepha-
pirin intrauterine infusion in cows with PVD or ENDO.
Therefore, the first objective of this study was to 
quantify the effect of an intrauterine infusion of cep-
hapirin on reproductive performance at first service 
in postpartum dairy cows affected by PVD, ENDO-
CYTO, or ENDO-LE. The second objective was to 
determine if the presence of a prolonged anovulation 
period would influence the magnitude of the benefit 
from intrauterine cephapirin therapy.
MATERIALS AND METHODS
Holstein cows from 28 commercial dairy herds were 
enrolled in a randomized clinical trial conducted be-
tween October 2011 and December 2013 (26 herds were 
enrolled in the first year and 2 were enrolled in the 
second year of farm data collection). Herds were se-
lected by convenience based on being within a 250-km 
radius of St-Hyacinthe (Québec, Canada), on having 
a computerized record system, and on using an ovu-
lation synchronization protocol (Double-Ovsynch or 
Presynch-Ovsynch; systematic use of the same proto-
col within herd) to synchronize the first service of all 
cows around 70 DIM. Herd size ranged from 40 to 600 
cows with a median of 91 cows. In total, 22 herds were 
housed in tiestall barns and 6 herds were housed in 
freestall barns (milking parlor). All cows that calved in 
these herds during the study period and that were bred 
at least once before 100 DIM were enrolled in the trial. 
Reproductive performance of these cows was recorded 
until 200 DIM. All herds used exclusively AI for breed-
ing. Pregnancy diagnosis was performed by transrectal 
palpation between 33 and 47 d after insemination. Each 
cow could only be enrolled once in the study. The esti-
mated sample size needed for this study was 2,344 cows. 
This sample size was planned to identify a difference of 
10% in pregnancy risk at first service between treated 
(30%) and untreated (20%) cows with 95% confidence 
and 80% power (Dohoo et al., 2009) when expecting a 
disease prevalence of 25%.
Farms were visited biweekly (every 14 d) by an ani-
mal health technician and a veterinarian. Cows were 
examined for PVD, ENDO-CYTO, and ENDO-LE at 
35 (±7) DIM. Purulent vaginal discharge was diagnosed 
first using vaginal discharge score assessed with the Met-
richeck device (0 = no discharge, 1 = clear mucus, 2 = 
mucus with flecks of pus, 3 = mucopurulent discharge, 
4 = purulent discharge or 5 = foul smelling discharge; 
McDougall et al., 2007). Diagnostic of ENDO-CYTO 
was done using a cytobrush technique (endometrial cy-
tology) adapted for use in cattle (Kasimanickam et al., 
2004; Dubuc et al., 2010) and diagnostic of ENDO-LE 
was done using an LE technique (Couto et al., 2013). 
Immediately after collection, the cytobrush was rolled 
on a microscope glass slide to obtain a smear. After 
that, the cytobrush was placed in an individual 3-mL 
glass vial containing 1 mL of 0.9% saline (NaCl 0.9% Ir-
rigation, Baxter Corp., Mississauga, ON, Canada). The 
microscope slides were stained within 12 h of collection 
with a modified Wright-Giemsa stain (Hema3; Biochem-
ical Sciences, Swedesboro, NJ) and glass coverslips were 
applied when dry as previously described (Dubuc et al., 
2010). The percentage of PMNL on these slides was de-
termined using a microscope (400× magnification) and 
slides were read by 2 observers (an animal health tech-
nician and a veterinarian). Two hundred cells (PMNL 
and endometrial cells) were counted on each slide. Slide 
readers were blinded to on-farm findings and treatment 
allocation. Within 12 h of collection, the individual vial 
containing the cytobrush was shaken for 10 s and a 
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drop of the solution was put on a commercial LE test 
strip (Multistix 10 SG; Bayer Corporation, Elkart, IN) 
using a pipette. Because of material availability, LE 
testing only began in December 2011 even though farm 
visits started in November 2011. The LE strip results 
of every cow were read after 2 min according to the 
manufacturer’s colorimetric chart, and the score was 
recorded as 0 = negative, 0.5 = trace of leukocytes, 1 
= small amount of leukocytes, 2 = moderate amount of 
leukocytes, and 3 = large amount of leukocytes (Couto 
et al., 2013). Test readers were blinded to on-farm find-
ings and treatment allocation.
Diagnostic criteria for PVD and ENDO were defined 
based on the optimal threshold to predict pregnancy 
status at first service in a subsample of cows that only 
included untreated cows. The approach to identify 
optimal thresholds was based on finding the logistic 
regression model with the lowest Akaike information 
criteria value after considering all combinations of 
PVD and ENDO test results (Burnham and Anderson, 
1998). In the end, one model was retained for the op-
timal pair of diagnostic criteria when simultaneously 
considering vaginal discharge and endometrial cytology 
results (PVD and ENDO-CYTO). Another model was 
retained for the optimal pair of diagnostic criteria when 
considering vaginal discharge and LE results (PVD and 
ENDO-LE). A complete description of this procedure 
is reported in the companion paper (Denis-Robichaud 
and Dubuc, 2015). The optimal diagnostic criteria for 
PVD in both models was a vaginal discharge score ≥4 
(purulent discharge or worse), whereas ENDO-CYTO 
was optimally defined as a percentage of PMNL ≥6% 
and ENDO-LE as a LE score ≥1 (small amounts of 
leukocytes).
Regardless of their reproductive tract health status 
at 35 (±7) DIM, cows were randomly assigned (using a 
predetermined random list within each herd) to receive 
1 of 2 treatments: (1) an intrauterine infusion of 500 
mg of cephapirin benzathin (Metricure, Merck Animal 
Health, Kirkland, QC, Canada; treatment group), or 
(2) no treatment (negative control group). It was im-
possible to blind producers from treatment allocation 
because cows in the control group did not receive any 
treatment. However, producers agreed not to perform 
any treatment until pregnancy diagnosis after first ser-
vice was done.
At 35 (±7) and 49 (±7) DIM (14 d apart), a blood 
sample (10 mL) was drawn from the coccygeal vessels 
of every enrolled cow into an evacuated tube without 
additive (Vacutainer; Becton Dickinson, Franklin 
Lakes, NJ). Samples were kept on ice and allowed to 
clot. Within 12 h of collection, samples were centri-
fuged and serum was harvested and frozen at −20°C. 
These samples were submitted for progesterone mea-
surement at the diagnostic laboratory of the Faculté 
de Médecine Vétérinaire of the Université de Montréal 
(St-Hyacinthe, QC, Canada) using a sequential com-
petitive immunoassay (Immulite; Siemens, Mississauga, 
ON, Canada) validated for use in cattle (Martin et al., 
2007). The inter- and intraassay coefficients of varia-
tion for progesterone were 8.2 and 7.1%, respectively. 
A cow was considered to have a prolonged anovulation 
period if both progesterone samples, taken 14 d apart, 
had values <1 ng/mL.
All statistical analyses were performed using SAS 9.3 
(SAS Institute Inc., Cary, NC) considering the cow as 
the unit of interest. Individual cow data such as par-
ity group (first, second or greater), season of calving 
(winter: January to March; spring: April to June, sum-
mer: July to September, fall: October to December), 
and reproductive and culling events were exported from 
the computerized record system (DSAHR Inc., Saint-
Hyacinthe, QC, Canada) to Excel (Microsoft Corp., 
Redmond, WA).
Descriptive statistics were calculated (PROC FREQ 
and PROC MEANS of SAS). Prevalence of lactation 
group, season of calving, reproductive tract disease, 
anovulation status, and pregnancy at first service were 
calculated overall and stratified by cephapirin treat-
ment groups (PROC FREQ). Interobserver agreement 
was calculated in a random subsample of 100 results for 
vaginal discharge, LE, and cytology, and intraobserver 
agreement was calculated for 100 endometrial cytology 
slides (Dohoo et al., 2009). Univariable associations 
(Pearson Chi-squared) between cephapirin treatment 
and reproductive tract disease, between cephapirin 
treatment and prolonged anovulation, and between 
cephapirin treatment and reproductive performance at 
first service were assessed in mixed logistic regression 
models accounting for herd clustering (random inter-
cept; PROC GLIMMIX).
Four multivariable mixed logistic regression mod-
els (PROC GLIMMIX) were used to quantify the 
association between cephapirin treatment and preg-
nancy status at first service. Lactation and season 
of calving were offered to all models as confounders, 
and were kept as a fixed effect if their effect on the 
model estimates was greater than 10% (Maldonado and 
Greenland, 1993). All models were forced to include 
the following variables: prolonged anovulation status, 
reproductive tract disease, cephapirin treatment, and 
2 interaction terms (cephapirin treatment × reproduc-
tive tract disease; cephapirin treatment × anovulation 
status). All models accounted for the random effect of 
herd (random intercept). A manual backward elimina-
tion procedure was used to build models until P-values 
were <0.05 (Dohoo et al., 2009). Cows unaffected by 
reproductive tract disease were used as the referent for 
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the reproductive tract disease variable in all models. A 
first model was built to assess the effect of cephapirin 
treatment on reproduction at first service in cows using 
PVD and ENDO-CYTO as diagnostic tools. A second 
model was built to assess the effect of cephapirin treat-
ment on reproduction at first service in cows affected 
by PVD only, ENDO-CYTO only, or both PVD and 
ENDO-CYTO at the same time. A third model was 
computed to assess the effect of cephapirin treatment 
on reproduction at first service in cows using PVD and 
ENDO-LE as diagnostic tools. A fourth model was 
built to quantify the effect of cephapirin treatment on 
reproduction at first service in cows affected by PVD 
only, ENDO-LE only, or both PVD and ENDO-LE at 
the same time. For each model, least squares means 
(LSM) for cephapirin treatment, reproductive tract 
disease, anovulation status, and for interaction terms 
(cephapirin treatment × reproductive tract disease; 
cephapirin treatment × anovulation status) were ob-
tained (PROC GLIMMIX). Differences between LSM 
were calculated using a Tukey-Kramer test. Statistical 
significance was defined as P-values <0.05.
RESULTS
Data from 2,506 Holstein cows were collected during 
the study period, but LE testing was only performed on 
2,135 cows for logistical reasons (material unavailable 
during the first month of the study in 26 herds). Of 
all the cows initially enrolled in the study, 235 were 
excluded because they were culled before pregnancy 
diagnosis was performed at first service (115 cows in 
group control; 120 cows in cephapirin treatment group; 
P = 0.91), and 12 more cows were excluded because 
they were bred for the first time after 100 DIM (5 cows 
in group control; 7 cows in cephapirin treatment group; 
P = 0.87). In the end, 2,259 cows were used for analysis 
during the study period and 1,900 cows were tested 
for LE. Of all cows enrolled in the study, 31.2% (n 
= 705) and 68.8% (n = 1554) were primiparous and 
multiparous cows, respectively. The distribution of 
cows within season of calving was 14.2% (n = 321) for 
winter, 14.5% (n = 328) for spring, 32.1% (n = 725) 
for summer, and 39.2% (n = 885) for fall. The overall 
prevalence of PVD in this study was 18.8% (n = 424) 
and ranged from 3.9 to 40.9% in participating herds. 
The overall prevalence of ENDO-CYTO was 35.1% (n 
= 793; from 9.3 to 66.2% in herds) and prevalence of 
ENDO-LE was 49.2% (n = 934; from 2.3 to 91.2% in 
herds). The prevalence of cows unaffected by PVD and 
ENDO-CYTO was 56.6% (n = 1278). Out of the 424 
cows affected by PVD in this study, 233 cows (55.0%) 
also had ENDO-CYTO at the same time. The overall 
prevalence of prolonged anovulation and pregnancy at 
first service were 26.9% (n = 607) and 28.6% (n = 646), 
respectively.
Interobserver agreement (kappa) was 0.791 (95% 
CI: 0.639–0.931) for vaginal discharge, 0.768 (95% CI: 
0.483–0.935) for PMNL percentage, and 0.922 (95% 
CI: 0.846–0.999) for LE. Intraobserver agreement 
(kappa) for each observers (n = 2) were 0.754 (95% 
CI: 0.551–0.822) and 0.739 (95% CI: 0.486–0.898) for 
PMNL percentage.
Univariable associations between cephapirin treat-
ment and various variables such as reproductive tract 
disease, anovulation status, and pregnancy at first ser-
vice are reported in Table 1. In total, 51.1% (n = 1,154) 
were treated with cephapirin in the study, whereas 
48.9% (n = 1,105) were not treated (negative control 
group; P = 0.13). In the subsample of cows tested for 
ENDO-LE (1,900 cows), 50.5% (n = 960) were treated 
with cephapirin in the study, whereas 49.5% (n = 940) 
were not treated (negative control group; P = 0.43).
Four final mixed multivariable logistic regression 
models were built to assess the association between 
cephapirin treatment and first-service pregnancy risk 
when considering different reproductive tract disease 
diagnosis approaches. The first model was built to 
evaluate this association when accounting for PVD and 
ENDO-CYTO (Table 2; n = 2,259 cows). The interpre-
tation of this model can be difficult because multiple 
2-way interaction terms are present. To facilitate the 
interpretation, LSM of first-service pregnancy risk from 
this model stratified by cephapirin treatment status 
are presented in Figure 1. This figure shows that in-
trauterine cephapirin treatment increased first-service 
pregnancy risk in cows affected by PVD (no treatment: 
14.5%; cephapirin: 30.9%; P < 0.01) and ENDO-CYTO 
(no treatment: 16.6%; cephapirin: 25.9%; P < 0.01) but 
not in unaffected cows (no treatment: 34.5%; cephapi-
rin: 31.8%; P = 0.54). Figure 1 also shows that cepha-
pirin treatment increased first-service pregnancy risk in 
ovular cows (no treatment: 22.7%; cephapirin: 34.1%; P 
< 0.01) but not in anovular cows (no treatment: 21.0%; 
cephapirin: 26.5%; P = 0.10).
Least squares means from the second model (n = 
2,259 cows) show that intrauterine cephapirin treat-
ment was associated with an increased first-service 
pregnancy risk in cows only affected by PVD (no treat-
ment: 14.2%; cephapirin: 30.6%; P < 0.01), in cows 
only affected by ENDO-CYTO (no treatment: 16.1%; 
cephapirin: 26.3%; P < 0.01), and in cows affected by 
both PVD and ENDO-CYTO at the same time (no 
treatment: 8.7%; cephapirin: 23.4%; P = 0.03) but not 
in cows unaffected by reproductive tract disease (no 
treatment: 32.6%; cephapirin: 31.5%; P = 0.86)
The third model was built to account for PVD and 
ENDO-LE (Table 3; n = 1,900 cows). Figure 2 presents 
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Table 1. Univariable associations between intrauterine cephapirin treatment at 35 (±7) DIM and reproductive tract disease status, anovulation 




Total no. (number for LE2 testing) 1,105 (960) 1,154 (940)  
Parity (yr)    
 Mean (±SD) 2.4 (0.8) 2.4 (0.9) 0.99
DIM at examination    
 Mean (±SD) 35.1 (3.8) 35.3 (4.1) 0.99
Prevalence of reproductive tract disease (%; no./total)    
 PVD3 18.1 (200/1,105) 20.6 (238/1,154) 0.14
 ENDO-CYTO4 24.6 (272/1,105) 23.8 (275/1,154) 0.63
 ENDO-LE5 22.9 (253/1,105) 20.8 (240/1,154) 0.32
Prevalence of prolonged anovulation (%; no./total)6    
 Overall 26.7 (295/1,105) 27.3 (315/1,154) 0.42
 In cows with PVD 30.9 (64/207) 27.6 (60/217) 0.21
 In cows with ENDO-CYTO 35.1 (136/388) 33.3 (135/405) 0.35
 In cows with ENDO-LE 30.1 (142/472) 30.3 (140/462) 0.80
 In unaffected cows 22.7 (142/625) 22.1 (144/653) 0.71
Pregnant at first service (%; no./total)    
 Overall 26.5 (293/1,105) 30.2 (349/1,154) 0.02
 In cows with PVD 15.5 (32/207) 31.3 (68/217) <0.01
 In cows with ENDO-CYTO 16.2 (63/388) 24.4 (99/405) <0.01
 In cows with ENDO-LE 15.9 (75/472) 25.1 (116/462) <0.01
 In unaffected cows 34.9 (218/625) 32.6 (213/653) 0.50
1Adjusted for herd clustering (random intercept).
2Leukocyte esterase.
3Purulent vaginal discharge defined as PVD or worse (≥4) using the Metricheck technique (Simcro, Hamilton, New Zealand).
4Endometritis defined as ≥6% PMNL at endometrial cytology using the cytobrush technique.
5Endometritis defined as small amounts of leukocyte or worse (≥1) using the leukocyte esterase technique.
6Prolonged anovulation defined as serum progesterone <1 ng/mL at 35 and 49 (±7) DIM.
Table 2. Final mixed logistic regression model of first-service pregnancy risk, accounting for the random effect of herd, in 2,259 Holstein dairy 
cows from 28 herds enrolled in a clinical trial investigating the effect of intrauterine cephapirin treatment for reproductive tract disease based 
on vaginal discharge and endometrial cytology at 35 (±7) DIM
Predictor  Class % of cows1 Coefficient SE P-value
Intercept   −1.15 0.19 <0.01
Lactation group 1 31.2 Referent   
 ≥2 68.8 0.35 0.11 <0.01
Prolonged anovulation No2 76.3 Referent   
 Yes3 23.7 0.35 0.13 0.01
Reproductive tract disease Unaffected 56.5 Referent   
 PVD4 18.8 0.04 0.16 0.79
 ENDO-CYTO5 24.7 0.01 0.16 0.99
Cephapirin No 48.9 Referent   
 Yes 51.1 −0.97 0.25 <0.01
Cephapirin × reproductive tract disease No × Unaffected 8.3 1.07 0.28 <0.01
 No × PVD 12.4    
 No × ENDO-CYTO 27.7    
 Yes × Unaffected 11.2    
 Yes × PVD 11.8    
 Yes × ENDO-CYTO 28.7    
Cephapirin × anovulation No × No 33.6 −0.10 0.28 0.67
 No × Yes 14.6    
 Yes × No 39.5    
 Yes × Yes 23.7    
1Proportion of cows in each category of predictor; within each predictor the sum is 100%.
2Serum progesterone ≥1 ng/mL at 35 or 49 (±7) DIM or both.
3Serum progesterone <1 ng/mL at 35 and 49 (±7) DIM.
4Purulent vaginal discharge defined as PVD or worse (≥4) using the Metricheck technique (Simcro, Hamilton, New Zealand).
5Endometritis defined as ≥6% PMNL at endometrial cytology using the cytobrush technique.
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LSM from this model. This figure illustrates that in-
trauterine cephapirin treatment increased first-service 
pregnancy risk in cows affected by PVD (no treatment: 
14.2%; cephapirin: 30.4%; P < 0.01) and ENDO-LE (no 
treatment: 16.6%; cephapirin: 29.9%; P < 0.01) but not 
in unaffected cows (no treatment: 32.1%; cephapirin: 
30.6%; P = 0.73). This figure also shows that cephapi-
rin treatment increased first-service pregnancy risk in 
ovular cows (no treatment: 25.5%; cephapirin: 33.9%; P 
< 0.01) but not in anovular cows (no treatment: 21.4%; 
cephapirin: 23.8%; P = 0.81).
From the fourth model (n = 1,900 cows), LSM show 
an increased first-service pregnancy risk in cows only 
affected by PVD (no treatment: 14.8%; cephapirin: 
30.1%; P < 0.01), in cows only affected by ENDO-LE 
(no treatment: 15.9%; cephapirin: 28.9%; P < 0.01), 
and in cows affected by both PVD and ENDO-LE (no 
treatment: 9.8%; cephapirin: 23.1%; P = 0.04), but not 
in cows unaffected by reproductive tract disease (no 
treatment: 31.9%; cephapirin: 30.6%; P = 0.96).
DISCUSSION
This study is one of the first to quantify the effect 
of intrauterine cephapirin therapy in postpartum dairy 
cows when considering diagnosis of PVD and ENDO 
simultaneously at 35 (±7) DIM. Such an approach al-
lows quantification of the overall effect of treatment on 
the subsequent reproductive performance of dairy cows 
affected by reproductive tract disease. As expected at 
the start of the study, intrauterine cephapirin therapy 
had a positive effect on first-service pregnancy risk 
and this effect was modulated by reproductive tract 
health status. Cows affected by PVD, ENDO-CYTO, 
or ENDO-LE had improved first-service pregnancy 
risk compared with untreated cows (Figures 1 and 2). 
For PVD, the magnitude of this improvement was 16 
percentage points on first-service pregnancy risk, which 
is consistent with previous studies reporting a similar 
benefit of using cephapirin therapy in cows affected by 
PVD (LeBlanc et al., 2002b; Runciman et al., 2008). 
For ENDO-CYTO and ENDO-LE, the improvement 
on first-service pregnancy risk was 9 and 13 percent-
age points, respectively. A previous study reported a 
similar benefit of cephapirin treatment in cows with 
ENDO-CYTO (15 percentage points; Kasimanickam et 
al., 2005). Treatment benefit for cows with ENDO-LE 
as shown in the present study is novel and has not been 
reported previously. This finding supports the increas-
ing interest of diagnosing ENDO-LE on farms because 
this technique can provide cow-side results that can 
lead to immediate cow treatment when needed (Denis-
Robichaud and Dubuc, 2015). For cows having both 
PVD and ENDO-CYTO at the same time, treatment 
benefit on first-service pregnancy risk was 14 percent-
age points, whereas it was 13 percentage points for the 
combination of PVD and ENDO-LE. Such treatment 
benefit in cows simultaneously diagnosed with PVD 
Figure 1. Least squares means (± SEM) of intrauterine cephapirin treatment at 35 (±7) DIM on first-service pregnancy risk stratified by 
reproductive tract disease [unaffected, purulent vaginal discharge diagnosed by Metricheck technique (Simcro, Hamilton, New Zealand), or cyto-
logical endometritis diagnosed by endometrial cytobrush technique] and by prolonged anovulation [serum progesterone <1 ng/mL at 35 and 49 
(±7) DIM] in 2,259 Holstein cows enrolled in a randomized clinical trial. *Significant effect of treatment within strata (P < 0.05).
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Table 3. Final mixed logistic regression model of first-service pregnancy risk, accounting for the random effect of herd, in 1,900 Holstein dairy 
cows from 28 herds enrolled in a clinical trial investigating the effect of intrauterine cephapirin treatment for reproductive tract disease based 
on vaginal discharge and leukocyte esterase at 35 (±7) DIM
Predictor  Class % of cows1 Coefficient SE P-value
Intercept   −1.30 0.20 <0.01
Lactation group 1 31.2 Referent   
 ≥2 68.8 0.36 0.11 <0.01
Prolonged anovulation No2 76.3 Referent   
 Yes3 23.7 0.45 0.12 <0.01
Reproductive tract disease Unaffected 59.4 Referent   
 PVD4 19.0 0.01 0.16 0.96
 ENDO-LE5 21.6 0.21 0.18 0.26
Cephapirin No 49.5 Referent   
 Yes 50.5 −0.75 0.25 <0.01
Cephapirin × reproductive tract disease No × Unaffected 8.3 0.91 0.27 <0.01
 No × PVD 11.5    
 No × ENDO-LE 28.5    
 Yes × Unaffected 11.2    
 Yes × PVD 10.2    
 Yes × ENDO-LE 30.3    
Cephapirin × anovulation No × No 32.1 −0.02 0.27 0.99
 No × Yes 19.9    
 Yes × No 30.0    
 Yes × Yes 18.0    
1Proportion of cows in each category of predictor; within each predictor, the sum is 100%.
2Serum progesterone ≥1 ng/mL at 35 or 49 (±7) DIM or both.
3Serum progesterone <1 ng/mL at 35 and 49 (±7) DIM.
4Purulent vaginal discharge defined as PVD or worse (≥4) using the Metricheck technique (Simcro, Hamilton, New Zealand).
5Endometritis defined as endometrial leukocyte esterase score ≥1 (small amounts of leukocytes).
Figure 2. Least squares means (± SEM) of intrauterine cephapirin treatment at 35 (±7) DIM on first-service pregnancy risk stratified by 
reproductive tract disease [unaffected, purulent vaginal discharge diagnosed by Metricheck technique (Simcro, Hamilton, New Zealand), or 
cytological endometritis diagnosed by endometrial leukocyte esterase technique] and by prolonged anovulation [serum progesterone <1 ng/mL 
at 35 and 49 (±7) DIM] in 1,900 Holstein cows enrolled in a randomized clinical trial. *Significant effect of treatment within strata (P < 0.05).
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and ENDO-CYTO or with PVD and ENDO-LE has 
never been reported before. Not surprisingly, cephapi-
rin therapy did not improve first-service reproductive 
performance in cows unaffected by reproductive tract 
disease, which is consistent with another report (Kasi-
manickam et al., 2005).
A goal of the present study was to determine whether 
prolonged postpartum anovulation influences the mag-
nitude of the benefit of cephapirin treatment. To ad-
dress this objective, the interaction term cephapirin 
treatment × anovulation status was forced in all multi-
variable models. Not surprisingly, the interaction term 
was not significant in final models as the sample size 
targeted for this study was focused on finding a sig-
nificant effect of treatment in cows with reproductive 
tract disease. A sufficient sample size for this objective 
would have been around 10,000 cows based on a priori 
calculations. Thus, we expected that the statistical 
power would be insufficient for this 2-way interaction 
term in all models but it was forced to calculate LSM. 
Therefore, differences between LSM from this 2-way 
interaction term were used to determine if the effect of 
cephapirin treatment was significant. As expected at 
the start of the study, the benefit of treating reproduc-
tive tract disease cows with cephapirin was influenced 
by postpartum anovulation status. More specifically, 
cephapirin treatment increased first-service pregnancy 
risk of ovular cows by 8 to 12 percentage points, where-
as it increased first-service pregnancy risk in anovular 
cows by only 1 to 5 percentage points, which was not 
statistically significant. Interestingly, LeBlanc et al. 
(2002b) showed that intrauterine cephapirin treatment 
had a smaller effect on reproductive performance when 
no corpus luteum was palpable in cows with PVD at 27 
to 33 DIM (as a proxy for prolonged anovulation) com-
pared with when cows had a palpable corpus luteum. 
Results from LeBlanc et al. (2002b) and the present 
study are consistent and suggest that anovular cows 
obtain less benefit from cephapirin therapy than ovular 
cows. Considering these results, it must be noted that 
categorization of prolonged anovulation in these data 
was across the entire population of cows and irrespec-
tive of reproductive tract disease status. Unfortunately, 
our sample size was insufficient to test whether intra-
uterine cephapirin treatment of anovular cows with 
reproductive tract disease was effective. However, these 
results suggest that the benefit of implementing a sys-
tematic intrauterine cephapirin treatment strategy for 
cows with reproductive tract disease in herds with high 
or low incidence of anovulation may be variable and 
needs to be clarified. It also remains unclear at this 
point why ovular cows had a greater magnitude of ben-
efit from cephapirin treatment than did anovular cows. 
Logically, intrauterine antibiotic treatment should re-
duce the uterine bacterial population, which otherwise 
would delay the process of uterine involution, as stated 
by LeBlanc et al. (2002b). A reduction in the bacterial 
population could reduce the presence of inflammation 
and improve subsequent reproductive performance. It is 
known that the presence of some bacteria in the uterus 
during the postpartum period can delay the resumption 
of ovarian function (Sheldon et al., 2009). Anovular 
cows could be infected by bacteria on which cephapirin 
would have a reduced or absent antibiotic effect. Future 
research should focus on identifying uterine bacteria 
in ovular and anovular cows. Another explanation for 
these results could be that the benefit of cephapirin 
treatment would be potentiated by evacuation of the 
uterine contents during estrus periods. Such uterine 
evacuation after cephapirin treatment could reduce the 
presence of inflammatory material in the uterus and 
subsequently lead to better treatment efficacy in ovular 
cows. Therefore, anovular cows could somehow benefit 
from a reduction in the bacterial population but might 
not evacuate uterine contents after treatment. This 
situation could reduce the benefit of cephapirin treat-
ment as inflammatory material would remain inside 
the uterus and interfere with embryo development (Hill 
and Gilbert, 2008). Further research is needed to better 
understand how prolonged anovulation influences the 
benefit of intrauterine treatment.
CONCLUSIONS
The use of intrauterine cephapirin treatment im-
proved first-service pregnancy risk in cows with PVD, 
ENDO-CYTO, or ENDO-LE, but not in cows unaffect-
ed by reproductive tract disease. The use of cephapirin 
treatment in cows affected by reproductive tract disease 
and prolonged postpartum anovulation only increased 
first-service pregnancy risk by 1 to 5 percentage points, 
whereas it was increased by 8 to 12 percentage points 
in ovular cows with similar reproductive tract disease. 
Further research should clarify how prolonged anovu-
lation potentiates the effect of intrauterine cephapirin 
treatment on subsequent reproduction in dairy cows.
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